DeepMed Research

Amgen, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1980-01-01

Employees: 26.7K

Market Cap: $175.6B

Website: http://www.amgen.com

Clinical Trials

A Phase 2a Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases

Phase 2

Not yet recruiting

Conditions: Systemic Lupus Erythematosus
Active Refractory Rheumatoid Arthritis

Interventions: Drug: Inebilizumab
Drug: Blinatumomab

First Posted Date: 2024-08-26

Last Posted Date: 2025-03-12

Lead Sponsor: Amgen

Target Recruit Count: 110

Registration Number: NCT06570798

Locations: 🇺🇸
Vitaly Clinical Research, Miami, Florida, United States
🇺🇸
Northwell Health, Great Neck, New York, United States
🇺🇸
Prolato Clinical Research Center, Houston, Texas, United States

and more 9 locations

A Study of TEPEZZA Subcutaneous Administration in Healthy Adults

Phase 1

Completed

Conditions: Bioavailability
Bioequivalence

Interventions: Drug: TEPEZZA
Drug: EDP

First Posted Date: 2024-08-21

Last Posted Date: 2024-08-21

Lead Sponsor: Amgen

Target Recruit Count: 37

Registration Number: NCT06563856

Locations: 🇺🇸
PPD Development, Las Vegas, Nevada, United States

Evaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic Castrate-sensitive Prostate Cancer

Phase 1

Recruiting

Conditions: Prostate Cancer
High-risk Biochemical Recurrence
High Risk Biochemical Recurrence of Non-metastatic Castration-sensitive Prostate Cancer
Non-metastatic Castration-sensitive Prostate Cancer

Interventions: Drug: Xaluritamig

First Posted Date: 2024-08-15

Last Posted Date: 2025-03-26

Lead Sponsor: Amgen

Target Recruit Count: 40

Registration Number: NCT06555796

Locations: 🇺🇸
Oregon Health and Science University, Portland, Oregon, United States
🇺🇸
University of Minnesota Medical Center Fairview, Minneapolis, Minnesota, United States
🇺🇸
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States

and more 5 locations

A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab in Prurigo Nodularis

Phase 3

Recruiting

Conditions: Prurigo Nodularis

Interventions: Drug: Rocatinlimab
Drug: Placebo

First Posted Date: 2024-07-30

Last Posted Date: 2025-05-15

Lead Sponsor: Amgen

Target Recruit Count: 460

Registration Number: NCT06527404

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
First OC Dermatology, Fountain Valley, California, United States
🇺🇸
Los Angeles Universal Research Center, Los Angeles, California, United States

and more 177 locations

Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment

Phase 2

Active, not recruiting

Conditions: Extensive Stage Small Cell Lung Cancer

Interventions: Drug: Tarlatamab

First Posted Date: 2024-07-16

Last Posted Date: 2025-04-16

Lead Sponsor: Amgen

Target Recruit Count: 32

Registration Number: NCT06502977

Locations: 🇨🇳
Tongji Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei, China
🇨🇳
The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
🇨🇳
Fujian Cancer Hospital, Fuzhou, China

and more 9 locations

A Study of Avacopan in Participants With Normal Renal Function and Participants With End-Stage Renal Disease (ESRD)

Phase 1

Completed

Conditions: End-Stage Renal Disease (ESRD)

Interventions: Drug: Avacopan

First Posted Date: 2024-06-21

Last Posted Date: 2024-10-15

Lead Sponsor: Amgen

Target Recruit Count: 13

Registration Number: NCT06468826

Locations: 🇺🇸
Floridian Clinical Research, LLC, Miami Lakes, Florida, United States
🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States

A Study to Evaluate Bioavailability of Rocatinlimab Autoinjector and Vial in Healthy Participants

Phase 1

Active, not recruiting

Conditions: Atopic Dermatitis

Interventions: Drug: Rocatinlimab

First Posted Date: 2024-05-31

Last Posted Date: 2025-02-04

Lead Sponsor: Amgen

Target Recruit Count: 231

Registration Number: NCT06438263

Locations: 🇺🇸
Fortrea Clinical Research Unit - Daytona Beach, Daytona Beach, Florida, United States
🇺🇸
Fortrea Clinical Research Unit Inc. - Madison, Madison, Wisconsin, United States

Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)

Phase 3

Recruiting

Conditions: Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC)

Interventions: Drug: ABP 234
Drug: Pembrolizumab

First Posted Date: 2024-05-28

Last Posted Date: 2025-05-15

Lead Sponsor: Amgen

Target Recruit Count: 154

Registration Number: NCT06430866

Locations: 🇮🇹
AUSL Della Romagna - Ospedale S.Maria delle Croci, Ravenna, Italy
🇷🇸
Clincial Centre of Serbia, Belgrade, Serbia
🇧🇬
University Multiprofile Hospital for Active Treatment Sofiamed, Sofia, Bulgaria

and more 103 locations

A Study to Assess the Effect of Olpasiran on QT/QTc Intervals in Healthy Participants

Phase 1

Completed

Conditions: Basic Science

Interventions: Drug: Olpasiran
Other: Placebo
Drug: Moxifloxacin

First Posted Date: 2024-05-13

Last Posted Date: 2024-12-20

Lead Sponsor: Amgen

Target Recruit Count: 32

Registration Number: NCT06411860

Locations: 🇬🇧
Fortrea Clinical Research Unit Limited - Leeds, Leeds, United Kingdom

A Study of TEPEZZA® Treatment in Participants With Thyroid Eye Disease

Phase 1

Completed

Conditions: Thyroid Eye Disease

Interventions: Drug: Teprotumumab

First Posted Date: 2024-04-29

Last Posted Date: 2024-06-21

Lead Sponsor: Amgen

Target Recruit Count: 16

Registration Number: NCT06389578

Locations: 🇺🇸
Bascom Palmer Eye Institute - University of Miami, Miami, Florida, United States
🇺🇸
Barnes Jewish Hospital Washington University, Saint Louis, Missouri, United States
🇺🇸
Neuro-Eye Clinical Trials, Bellaire, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy